
Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

